CSL Behring has signed a commercial agreement in Austria that will enable eligible patients with hemophilia B to access its one-time gene therapy, Hemgenix (etranacogene dezaparvovec), through a new dedicated supra-national fund for high-priced and specialized medicines.
A spokesperson for the company told the Pink Sheet that Austria introduced the fund as part of the latest Financial Redistribution Agreement, which came into effect on 1 January, and that